Equibles does not estimate personal net worth.
Get an email with a short summary when Acurx Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get ACXP alertsRobert Shawah is recorded as CFO at Acurx Pharmaceuticals, Inc. (ACXP). The proxy statement of Acurx Pharmaceuticals, Inc. reports total compensation of $907,463 for Robert Shawah in fiscal 2024, including a base salary of $395,840. Disclosed compensation is on record for 5 fiscal years. Robert Shawah has spoken on 11 earnings calls across 1 company, most recently for Acurx Pharmaceuticals, Inc. on September 30, 2025. Acurx Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Acurx Pharmaceuticals, Inc. includes David P. Luci (CEO and Board Member), Robert DeLuccia (Chairman), Carl V. Sailer (Board Member) and 4 others.
“This morning, we issued a press release providing financial results and company highlights for the third quarter of 2025, which is available on our website at acurxpharma.com. Joining me today is Dave Luci, President and CEO of Acurx, who will give a corporate update and outlook.”
“This morning, we issued a press release providing financial results and company highlights for the first quarter 2025, which is available on our website at acurxpharma.com. Joining me today is Dave Luci, President and CEO of Acurx, who will give a corporate update and outlook.”
“This morning, we issued a press release providing financial results and company highlights for the fourth quarter and full year 2024, which is available on our website at acurxpharma.com. Joining me today is Dave Luci, President and CEO of Acurx, who will give a corporate update and outlook.”
“This morning, we issued a press release providing financial results and company highlights for the third quarter of 2024, which is available on our website at acurxpharma.com. Joining me today is Dave Luci, President and CEO of Acurx, who will give a corporate update and outlook.”
“This morning, we issued a press release providing financial results and company highlights for the second quarter 2024, which is available on our website at acurxpharma.com. Joining me today is Dave Luci, President and CEO, who will give a corporate update and outlook.”
Biotechnology · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Acurx Pharmaceuticals, Inc. (ACXP) | Chief Financial Officer | $395,840 | $907,463 |
| 2023 | Acurx Pharmaceuticals, Inc. (ACXP) | Chief Financial Officer | $375,000 | $675,038 |
| 2022 | Acurx Pharmaceuticals, Inc. (ACXP) | Chief Financial Officer | $300,000 | $375,000 |
| 2021 | Acurx Pharmaceuticals, Inc. (ACXP) | Chief Financial Officer | $170,050 | $1,462,738 |
| 2020 | Acurx Pharmaceuticals, Inc. (ACXP) | Chief Financial Officer | $90,000 | $152,500 |
